[go: up one dir, main page]

NO20062019L - P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme - Google Patents

P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme

Info

Publication number
NO20062019L
NO20062019L NO20062019A NO20062019A NO20062019L NO 20062019 L NO20062019 L NO 20062019L NO 20062019 A NO20062019 A NO 20062019A NO 20062019 A NO20062019 A NO 20062019A NO 20062019 L NO20062019 L NO 20062019L
Authority
NO
Norway
Prior art keywords
preparation
methods
same
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO20062019A
Other languages
English (en)
Other versions
NO336127B1 (no
Inventor
Gwan-Sun Lee
Keuk Chan Bang
Mi Yong Cha
Young Gil Ahn
Young Jin Ham
Maeng Sup Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of NO20062019L publication Critical patent/NO20062019L/no
Publication of NO336127B1 publication Critical patent/NO336127B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Structural Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Biotilgjengeligheten til et antikreftmiddel økes når antikreftmiddelet administreres sammen med et farmasøytisk preparat omfattende en forbindelse med formel (I) eller et farmasøytisk akseptabelt salt av dette.
NO20062019A 2003-10-07 2006-05-05 P-glykoproteininhibitor, fremgangsmåter for fremstilling av denne samt farmasøytisk preparat omfattende den samme NO336127B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030069582A KR100557093B1 (ko) 2003-10-07 2003-10-07 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PCT/KR2004/002550 WO2005033097A1 (en) 2003-10-07 2004-10-06 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Publications (2)

Publication Number Publication Date
NO20062019L true NO20062019L (no) 2006-07-06
NO336127B1 NO336127B1 (no) 2015-05-18

Family

ID=36500896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062019A NO336127B1 (no) 2003-10-07 2006-05-05 P-glykoproteininhibitor, fremgangsmåter for fremstilling av denne samt farmasøytisk preparat omfattende den samme

Country Status (22)

Country Link
US (1) US7625926B2 (no)
EP (1) EP1678162B1 (no)
JP (1) JP4481992B2 (no)
KR (1) KR100557093B1 (no)
CN (1) CN1863795B (no)
AT (1) ATE466008T1 (no)
AU (1) AU2004277475B2 (no)
BR (1) BRPI0415053B8 (no)
CA (1) CA2541301C (no)
DE (1) DE602004026903D1 (no)
DK (1) DK1678162T3 (no)
ES (1) ES2342290T3 (no)
IL (1) IL174665A (no)
MX (1) MXPA06003803A (no)
NO (1) NO336127B1 (no)
NZ (1) NZ546257A (no)
PL (1) PL1678162T3 (no)
PT (1) PT1678162E (no)
RU (1) RU2317985C1 (no)
SI (1) SI1678162T1 (no)
WO (1) WO2005033097A1 (no)
ZA (1) ZA200603538B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2372347C2 (ru) * 2004-02-18 2009-11-10 Астразенека Аб Соединения тетразола и их применение в качестве антагонистов метаботропного рецептора глутамата
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
EP2344474B1 (en) 2008-09-02 2015-09-23 Novartis AG Picolinamide derivatives as kinase inhibitors
KR101466245B1 (ko) 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
EA026432B1 (ru) 2012-05-21 2017-04-28 Новартис Аг Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20150135110A (ko) * 2014-05-23 2015-12-02 한미정밀화학주식회사 p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
EP3893867A1 (en) * 2018-12-14 2021-10-20 Athenex HK Innovative Limited Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancer
CN113631166A (zh) * 2018-12-14 2021-11-09 慧源香港创新有限公司 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合
US12404267B2 (en) 2019-02-14 2025-09-02 Assia Chemical Industries Ltd. Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
WO2020230037A1 (en) * 2019-05-13 2020-11-19 Dr. Reddy's Laboratories Limited Alternate process for the preparation of encequidar
WO2021044350A1 (en) * 2019-09-04 2021-03-11 Dr. Reddy’S Laboratories Limited Solid forms of encequidar mesylate and processes thereof
WO2022011221A1 (en) 2020-07-10 2022-01-13 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
EP4225747A1 (en) * 2020-10-07 2023-08-16 Athenex, Inc. Acetamido-phenyltetrazole derivatives and methods of using the same
CN116367836A (zh) * 2020-10-30 2023-06-30 艾斯尼克斯研发有限责任公司 Hm30181甲磺酸盐的多晶态
CN117603219B (zh) * 2023-11-29 2025-08-08 浙江大学 一种p-糖蛋白抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007844A1 (en) * 1990-11-06 1992-05-14 Pfizer Inc. Quinazolines derivatives for enhancing antitumor activity
JP3223193B2 (ja) * 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
US5663179A (en) 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US20030220402A1 (en) * 2000-02-15 2003-11-27 Naoki Tsuchiya Cancer remedy comprising anthranilic acid derivatives as active ingredients
EP1506188B1 (en) 2002-05-14 2009-02-25 Xenova Limited Process for the preparation of a hydrate of an anthranilic acid derivative
KR100580743B1 (ko) 2003-10-08 2006-05-15 한미약품 주식회사 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법

Also Published As

Publication number Publication date
EP1678162B1 (en) 2010-04-28
JP4481992B2 (ja) 2010-06-16
US7625926B2 (en) 2009-12-01
EP1678162A1 (en) 2006-07-12
ES2342290T3 (es) 2010-07-05
EP1678162A4 (en) 2008-07-02
WO2005033097A1 (en) 2005-04-14
DE602004026903D1 (de) 2010-06-10
BRPI0415053A (pt) 2006-11-28
KR100557093B1 (ko) 2006-03-03
PT1678162E (pt) 2010-05-19
MXPA06003803A (es) 2006-07-03
IL174665A0 (en) 2006-08-20
PL1678162T3 (pl) 2010-09-30
CN1863795B (zh) 2011-05-18
AU2004277475B2 (en) 2007-08-09
CA2541301A1 (en) 2005-04-14
RU2317985C1 (ru) 2008-02-27
BRPI0415053B1 (pt) 2019-12-31
RU2006114427A (ru) 2007-11-20
HK1096399A1 (en) 2007-06-01
CN1863795A (zh) 2006-11-15
US20070072900A1 (en) 2007-03-29
ATE466008T1 (de) 2010-05-15
AU2004277475A1 (en) 2005-04-14
JP2007507493A (ja) 2007-03-29
SI1678162T1 (sl) 2010-07-30
CA2541301C (en) 2010-02-02
KR20050033734A (ko) 2005-04-13
DK1678162T3 (da) 2010-08-02
IL174665A (en) 2012-10-31
ZA200603538B (en) 2007-09-26
NO336127B1 (no) 2015-05-18
NZ546257A (en) 2009-09-25
BRPI0415053B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20062019L (no) P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme
EA200401318A1 (ru) Производные хинолинона
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
HUP0401963A2 (hu) Karbonsavszármazékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
MXPA05009985A (es) Ligandos de receptores de canabinoides.
EP1939175A4 (en) SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
BR0010520A (pt) Novos compostos farmaceuticamente ativos
HRP20041211B1 (hr) Topikalno primjenjivi farmaceutski pripravak
ATE475652T1 (de) Chinazolinderivate
ATE450533T1 (de) Carboxamidderivate
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO333265B3 (no) Substituerte dihydrokinazoliner, fremgangsmåte for fremstilling derav, anvendelse av en slik forbindelse samt medikament inneholdende denne.
EP1498127A4 (en) USE OF AN ANTITUMORAL INDOLOPYRROLOCARBAZOL DERIVATIVE AND OTHER COMBINED CANCER
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2004014868A3 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
EA200600377A1 (ru) Новая композиция
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
HUP0301334A2 (hu) Szubsztituált akriloil-disztamicin-származékokat és taxánokat és/vagy antimetabolitokat tartalmazó kombinált tumorellenes kompozíciók
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
HUP0003555A2 (hu) Gombaellenes hatású triazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és intermedierjük
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS